Article
CRY1 fuels resistance to T cell-based immunotherapy in NANOGhigh cancers
2025-01-08
Abstract excerpt
<title>Abstract</title> <p> Cancer immunotherapies, including immune checkpoint blockade (ICB), have marked a significant breakthrough in cancer treatment but their clinical efficacy is limited in immune-resistant tumors. Previously, we found that immunotherapy-mediated immune selection enriches immune-resistant tumors with both tumor-intrinsic and -extrinsic refractory phenotypes via the transcriptional inducti...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0ed957e1-dd76-58f6-bd83-9f36364de27f
- DOI
- 10.21203/rs.3.rs-5658722/v1
